PRODUCT CANDIDATES
TRU-015 for the Treatment of Rheumatoid Arthritis
SBI-087 for the Treatment of Rheumatoid Arthritis
In the first half of 2008, Wyeth initiated a Phase I clinical trial for SBI-087, our next generation CD20 product candidate for the treatment of RA. The Phase 1 SBI-087 dose-escalation clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of SBI-087 in patients with RA.
Preclinical research suggests that SBI-087, a fully humanized CD20-directed SMIP, has enhanced potency in B-cell depletion in vivo compared with Rituxan. The Phase 1 trial is designed to enroll patients who meet the criteria for RA with Functional Class I, II or III, and who have been diagnosed with RA more than six months before the study with onset of RA after the age of 16.
With SBI-087, Trubion’s pipeline includes two differentiated compounds under development for the treatment of autoimmune and inflammatory diseases. Trubion and Wyeth are leveraging Trubion’s SMIP™ technology to create a portfolio of product candidates with customized mechanisms of action in an effort to optimize patient safety, efficacy and convenience.
Click here for additional information on clinical trials evaluating SBI-087 for RA
2008 Nature Biotech CD20 Blockers in RA